BCAL Diagnostics Limited (AU:BDX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BCAL Diagnostics Limited has achieved a significant milestone with the accreditation of its North Ryde laboratory by the National Association of Testing Authorities Australia (NATA). This accreditation paves the way for the commercial launch of their innovative breast cancer detection test, BREASTEST, in partnership with Sydney Breast Clinic. The advancement underscores BCAL’s commitment to providing high-quality breast cancer screening solutions, enhancing early detection and intervention opportunities.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.